Biocatalysis
Information and Commentary About Biofuels and Biotechnology
-
Biocatalysis Bummer
Filed under biocatalysisFeb 25Drug cancellations are the bane of the existence of biocatalysis developers. A nicely selective, efficient enzymatic process is developed, tested, and just as commercialization seems at hand, the drug gets pulled. Pfizer just announced such a cancellation for esreboxetine. Two chiral centers down the drain.
Leave a Reply
You must be logged in to post a comment.
Links
Recent Articles
- The Largest Biofuels Deal in the History of the World–So Far
- An Unexpected Environmentalist
- Biofuels Company LS9 Claims Major Breakthrough
- A Solar-Powered iPod?
- Fishing for Biofuels
- Fuel From Thin Air
- Could Tobacco Gain Acceptance as a Biofuel Crop?
- Solazyme Shifts Near-Term Focus to Food Ingredients
- New Biofuels Top 50 Released
- WSJ: Algae Could Change Everything
Categories
- algae (16)
- biocatalysis (34)
- biocatalyst (8)
- Biodegradation (1)
- biodiesel (3)
- biofuels (67)
- Biofuels companies (52)
- biotransformation (5)
- cellulosic ethanol (14)
- chiral amines (1)
- DSM (1)
- Enzymes (7)
- global warming (1)
- metabolite (1)
- Resources (2)
- succinic acid (1)
- Uncategorized (1)
- white biotechnology (3)